Star drugs like BM­S' Op­di­vo, As­traZeneca's Lyn­parza will get speedy OKs in Chi­na this year, new re­port pre­dicts

Now that Chi­na has re­vamped its drug re­view process to speed things up for de­vel­op­ers, a new re­port pre­dicts that Bris­tol-My­ers Squibb $BMY, As­traZeneca $AZN and Am­gen $AMGN are among the lead­ing multi­na­tion­al phar­ma gi­ants that will win ap­proval for some block­buster hope­fuls. Oth­ers stand to ben­e­fit from mar­ket­ing drugs de­vel­oped by Chi­nese part­ners.

The re­port, pro­duced by Bei­jing-based da­ta provider Pharm­Cube, high­lights 16 prod­ucts Chi­nese reg­u­la­tors are ex­pect­ed to green light in 2018. Over half of them in­volve an over­seas play­er in bio­phar­ma.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER